Published in Science on January 24, 1992
mdm2 expression is induced by wild type p53 activity. EMBO J (1993) 8.01
When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer (2009) 5.86
Mutant p53: one name, many proteins. Genes Dev (2012) 4.33
Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc Natl Acad Sci U S A (1992) 4.06
The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription. Proc Natl Acad Sci U S A (2000) 4.01
Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol (2010) 3.65
Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding. Mol Cell Biol (1992) 3.37
PML, a growth suppressor disrupted in acute promyelocytic leukemia. Mol Cell Biol (1994) 2.68
The human ARF cell cycle regulatory gene promoter is a CpG island which can be silenced by DNA methylation and down-regulated by wild-type p53. Mol Cell Biol (1998) 2.53
Human papillomavirus E6 proteins bind p53 in vivo and abrogate p53-mediated repression of transcription. EMBO J (1992) 2.45
Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene. Mol Med (1995) 2.44
p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol Cell Biol (1999) 2.41
Increased activity of p53 in senescing fibroblasts. Proc Natl Acad Sci U S A (1995) 2.27
Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. Proc Natl Acad Sci U S A (1996) 2.09
Mutant KRAS Enhances Tumor Cell Fitness by Upregulating Stress Granules. Cell (2016) 2.03
Mutant p53 gain-of-function induces epithelial-mesenchymal transition through modulation of the miR-130b-ZEB1 axis. Oncogene (2012) 1.85
Inhibition of viral and cellular promoters by human wild-type p53. J Virol (1992) 1.83
Two domains of p53 interact with the TATA-binding protein, and the adenovirus 13S E1A protein disrupts the association, relieving p53-mediated transcriptional repression. Mol Cell Biol (1995) 1.73
Relief of p53-mediated transcriptional repression by the adenovirus E1B 19-kDa protein or the cellular Bcl-2 protein. Proc Natl Acad Sci U S A (1994) 1.69
Activation of c-myc gene expression by tumor-derived p53 mutants requires a discrete C-terminal domain. Mol Cell Biol (1998) 1.62
The MYND motif is required for repression of basal transcription from the multidrug resistance 1 promoter by the t(8;21) fusion protein. Mol Cell Biol (1998) 1.58
New insights into p53 signaling and cancer cell response to DNA damage: implications for cancer therapy. J Biomed Biotechnol (2012) 1.57
p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer. Br J Cancer (2004) 1.56
Tumor-derived p53 mutants induce NF-kappaB2 gene expression. Mol Cell Biol (2005) 1.54
Modulation of cellular and viral promoters by mutant human p53 proteins found in tumor cells. J Virol (1992) 1.44
Visualization and enrichment of live putative cancer stem cell populations following p53 inactivation or Bax deletion using non-toxic fluorescent dyes. Cancer Biol Ther (2009) 1.43
Transcriptional activation of the human epidermal growth factor receptor promoter by human p53. Mol Cell Biol (1996) 1.37
Multidrug resistance 1 gene (P-glycoprotein 170): an important determinant in gastrointestinal disease? Gut (2003) 1.35
Physical and functional interaction between wild-type p53 and mdm2 proteins. Mol Cell Biol (1994) 1.34
Are RAS mutations predictive markers of resistance to standard chemotherapy? Nat Rev Clin Oncol (2009) 1.32
Proteolysis by calpains: a possible contribution to degradation of p53. Mol Cell Biol (1997) 1.30
neu/ERBB2 cooperates with p53-172H during mammary tumorigenesis in transgenic mice. Mol Cell Biol (1997) 1.27
p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study. Br J Cancer (1997) 1.21
p53-dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents. Proc Natl Acad Sci U S A (1997) 1.21
Molecular pathways: regulation and therapeutic implications of multidrug resistance. Clin Cancer Res (2012) 1.20
Phosphorylation at the carboxy terminus of the 55-kilodalton adenovirus type 5 E1B protein regulates transforming activity. J Virol (1994) 1.20
The helix-loop-helix containing transcription factor USF binds to and transactivates the promoter of the p53 tumor suppressor gene. Nucleic Acids Res (1993) 1.19
Mutant p53 can substitute for human papillomavirus type 16 E6 in immortalization of human keratinocytes but does not have E6-associated trans-activation or transforming activity. J Virol (1992) 1.18
p53 and bcl-2 expression in high-grade B-cell lymphomas: correlation with survival time. Br J Cancer (1994) 1.16
Modulation of the transcriptional activity of thyroid hormone receptors by the tumor suppressor p53. Proc Natl Acad Sci U S A (1996) 1.15
Induction of wild-type p53 activity in human cancer cells by ribozymes that repair mutant p53 transcripts. Proc Natl Acad Sci U S A (2000) 1.15
Inhibition of DNA topoisomerase II alpha gene expression by the p53 tumor suppressor. Mol Cell Biol (1997) 1.13
Increased p38-MAPK is responsible for chemotherapy resistance in human gastric cancer cells. BMC Cancer (2008) 1.11
Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients. Br J Cancer (2000) 1.11
Negative regulation of transcription in eukaryotes. Biochem J (1993) 1.10
Transcriptional repression by p53 involves molecular interactions distinct from those with the TATA box binding protein. Nucleic Acids Res (1996) 1.08
The tumor suppressor p53 regulates its own transcription. Mol Cell Biol (1993) 1.08
The consequence of oncomorphic TP53 mutations in ovarian cancer. Int J Mol Sci (2013) 1.07
The tumor suppressor protein p53 strongly alters human immunodeficiency virus type 1 replication. J Virol (1994) 1.06
DeltaNp73alpha regulates MDR1 expression by inhibiting p53 function. Oncogene (2007) 1.06
Reversal of in vitro p53 squelching by both TFIIB and TFIID. Mol Cell Biol (1995) 1.05
Regulation of expression of the multidrug resistance protein MRP1 by p53 in human prostate cancer cells. J Clin Invest (2000) 1.04
p53 mutants induce transcription of NF-κB2 in H1299 cells through CBP and STAT binding on the NF-κB2 promoter and gain of function activity. Arch Biochem Biophys (2011) 1.02
Mutant p53-R273H gains new function in sustained activation of EGFR signaling via suppressing miR-27a expression. Cell Death Dis (2013) 1.01
Prognostic value of p53 protein expression for patients with gastric cancer--a multivariate analysis. Br J Cancer (1999) 0.99
Transcriptional regulation of basic fibroblast growth factor gene by p53 in human glioblastoma and hepatocellular carcinoma cells. Proc Natl Acad Sci U S A (1994) 0.98
Ribozyme-mediated reversal of the multidrug-resistant phenotype. Proc Natl Acad Sci U S A (1994) 0.97
Wild-type human p53 transactivates the human proliferating cell nuclear antigen promoter. Mol Cell Biol (1995) 0.97
Regulation of breast cancer stem cell features. Contemp Oncol (Pozn) (2015) 0.97
Overexpression of P-glycoprotein in hepatocellular carcinoma and its clinical implication. World J Gastroenterol (2000) 0.96
Posttranslational phosphorylation of mutant p53 protein in tumor development. Med Mol Morphol (2006) 0.96
P-glycoprotein is not expressed in a majority of colorectal carcinomas and is not regulated by mutant p53 in vivo. Br J Cancer (1995) 0.95
Constitutive expression of the c-H-ras oncogene inhibits doxorubicin-induced apoptosis and promotes cell survival in a rhabdomyosarcoma cell line. Br J Cancer (1995) 0.95
Role of p53 in Cell Death and Human Cancers. Cancers (Basel) (2011) 0.95
RUNX Family Participates in the Regulation of p53-Dependent DNA Damage Response. Int J Genomics (2013) 0.95
Chemotoxicity of doxorubicin and surface expression of P-glycoprotein (MDR1) is regulated by the Pseudomonas aeruginosa toxin Cif. Am J Physiol Cell Physiol (2008) 0.94
Development of multidrug-resistance convertors: sense or nonsense? Invest New Drugs (2000) 0.93
Expression of P-glycoprotein in hepatocellular carcinoma: a potential marker of prognosis. J Clin Pathol (1996) 0.93
Silencing of mutant p53 by siRNA induces cell cycle arrest and apoptosis in human bladder cancer cells. World J Surg Oncol (2013) 0.93
Activation of the human immunodeficiency virus type 1 long terminal repeat by transforming mutants of human p53. J Virol (1994) 0.93
A proliferative p53-responsive element mediates tumor necrosis factor alpha induction of the human immunodeficiency virus type 1 long terminal repeat. Mol Cell Biol (1995) 0.92
ABCB1/MDR1 gene polymorphisms as a prognostic factor in colorectal cancer. Int J Colorectal Dis (2010) 0.92
p53 and P-glycoprotein are often co-expressed and are associated with poor prognosis in breast cancer. Br J Cancer (1996) 0.91
Specific interaction of mutant p53 with regions of matrix attachment region DNA elements (MARs) with a high potential for base-unpairing. Proc Natl Acad Sci U S A (1998) 0.91
Overcoming Multidrug Resistance in Cancer Stem Cells. Biomed Res Int (2015) 0.90
p53 Protein overexpression in cholangiocarcinoma arising in primary sclerosing cholangitis. Gut (1996) 0.89
A new model for studying tissue-specific mdr1a gene expression in vivo by live imaging. Proc Natl Acad Sci U S A (2009) 0.89
Modulation of MDR/MRP by wild-type and mutant p53. J Clin Invest (2001) 0.88
Hot-spot p53 mutants interact specifically with two cellular proteins during progression of the cell cycle. Mol Cell Biol (1994) 0.86
Isolation and characterization of DNA sequences that are specifically bound by wild-type p53 protein. Mol Cell Biol (1993) 0.86
A novel mechanism of Ha-ras oncogene action: regulation of fibronectin mRNA levels by a nuclear posttranscriptional event. Mol Cell Biol (1994) 0.85
Overcoming drug efflux-based multidrug resistance in cancer with nanotechnology. Chin J Cancer (2012) 0.85
Effects of mutant p53 expression on human 15-lipoxygenase-promoter activity and murine 12/15-lipoxygenase gene expression: evidence that 15-lipoxygenase is a mutator gene. Proc Natl Acad Sci U S A (1999) 0.85
Expression of mdr49 and mdr65 multidrug resistance genes in larval tissues of Drosophila melanogaster under normal and stress conditions. Cell Stress Chaperones (2005) 0.85
Involvement of the epidermal growth factor receptor in the modulation of multidrug resistance in human hepatocellular carcinoma cells in vitro. Cancer Cell Int (2011) 0.85
Upregulation of the mitochondrial transport protein, Tim50, by mutant p53 contributes to cell growth and chemoresistance. Arch Biochem Biophys (2011) 0.84
Transcriptional and post-transcriptional mechanisms can regulate cell-specific expression of the human Pi-class glutathione S-transferase gene. Biochem J (1997) 0.84
12-O-tetradecanoylphorbol-13-acetate activation of the MDR1 promoter is mediated by EGR1. Mol Cell Biol (1995) 0.83
Expression of chemoresistance-related genes and heat shock protein 72 in hyperthermic isolated limb perfusion of malignant melanoma: an experimental study. J Oncol (2010) 0.83
mdm2 gene mediates the expression of mdr1 gene and P-glycoprotein in a human glioblastoma cell line. Br J Cancer (1996) 0.83
p53 protein expression in nephroblastomas: a predictor of poor prognosis. Br J Cancer (1998) 0.83
High levels of the MDM2 oncogene in paediatric rhabdomyosarcoma cell lines may confer multidrug resistance. Br J Cancer (2001) 0.83
Bioimaging real-time PXR-dependent mdr1a gene regulation in mdr1a.fLUC reporter mice. J Pharmacol Exp Ther (2013) 0.82
Relationship between therapeutic efficacy of arterial infusion chemotherapy and expression of P-glycoprotein and p53 protein in advanced hepatocellular carcinoma. World J Gastroenterol (2006) 0.82
Therapy's Shadow: A Short History of the Study of Resistance to Cancer Chemotherapy. Front Pharmacol (2013) 0.81
Effects of p53 mutants derived from lung carcinomas on the p53-responsive element (p53RE) of the MDM2 gene. Br J Cancer (1998) 0.81
Overexpression of p53 mRNA in colorectal cancer and its relationship to p53 gene mutation. Br J Cancer (1997) 0.80
Clitocine reversal of P-glycoprotein associated multi-drug resistance through down-regulation of transcription factor NF-κB in R-HepG2 cell line. PLoS One (2012) 0.80
Cyclic AMP and fluconazole resistance in Saccharomyces cerevisiae. Antimicrob Agents Chemother (2000) 0.80
Application of an original RT-PCR-ELISA multiplex assay for MDR1 and MRP, along with p53 determination in node-positive breast cancer patients. Br J Cancer (2000) 0.80
The Rous sarcoma virus long terminal repeat is a strong promoter when introduced into a variety of eukaryotic cells by DNA-mediated transfection. Proc Natl Acad Sci U S A (1982) 20.55
Cyclic AMP receptor protein of E. coli: its role in the synthesis of inducible enzymes. Proc Natl Acad Sci U S A (1970) 13.26
Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem (1993) 10.95
Pleiotropic deficiency of carbohydrate utilization in an adenyl cyclase deficient mutant of Escherichia coli. Biochem Biophys Res Commun (1969) 9.20
Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell (1986) 8.53
Cyclic adenosine 5'-monophosphate in Escherichia coli. Bacteriol Rev (1976) 7.55
Regulation of beta-galactosidase synthesis in Escherichia coli by cyclic adenosine 3',5'-monophosphate. J Biol Chem (1968) 7.54
Cyclic adenosine monophosphate in bacteria. Science (1970) 7.53
Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci U S A (1987) 7.38
Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol (1999) 6.62
Direct visualization of binding, aggregation, and internalization of insulin and epidermal growth factor on living fibroblastic cells. Proc Natl Acad Sci U S A (1978) 6.59
Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci U S A (1987) 5.65
Identification of a functional promoter in the long terminal repeat of Rous sarcoma virus. Cell (1980) 5.51
Restoration of several morphological characteristics of normal fibroblasts in sarcoma cells treated with adenosine-3':5'-cyclic monphosphate and its derivatives. Proc Natl Acad Sci U S A (1971) 5.31
Dansylcadaverine inhibits internalization of 125I-epidermal growth factor in BALB 3T3 cells. J Biol Chem (1980) 5.24
Structure of the promoter for chicken alpha 2 type I collagen gene. Proc Natl Acad Sci U S A (1981) 4.89
In vitro transcription of the gal operon requires cyclic adenosine monophosphate and cyclic adenosine monophosphate receptor protein. J Biol Chem (1971) 4.58
Genetics and function of DNA ligase in Escherichia coli. J Mol Biol (1973) 4.52
Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A (1996) 4.49
Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci U S A (1987) 4.43
Localization of the src gene product of the Harvey strain of MSV to plasma membrane of transformed cells by electron microscopic immunocytochemistry. Cell (1980) 4.35
Cell surface protein partially restores morphology, adhesiveness, and contact inhibition of movement to transformed fibroblasts. Proc Natl Acad Sci U S A (1976) 4.32
Localization of the ASV src gene product to the plasma membrane of transformed cells by electron microscopic immunocytochemistry. Cell (1979) 4.30
Cyclic 3'5-AMP: stimulation of beta-galactosidase and tryptophanase induction in E. coli. Biochem Biophys Res Commun (1968) 4.16
Identification of two lysosomal membrane glycoproteins. J Cell Biol (1985) 4.08
Characterization and sequence of the promoter region of the human epidermal growth factor receptor gene. Proc Natl Acad Sci U S A (1985) 4.08
Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J Biol Chem (2000) 4.02
Epidermal-growth-factor-dependent transformation by a human EGF receptor proto-oncogene. Science (1987) 3.93
Collection of insulin, EGF and alpha2-macroglobulin in the same patches on the surface of cultured fibroblasts and common internalization. Cell (1978) 3.90
The receptosome: an intermediate organelle of receptor mediated endocytosis in cultured fibroblasts. Cell (1980) 3.88
Regulation of inducible enzyme synthesis in Escherichia coli by cyclic adenosine 3', 5'-monophosphate. J Biol Chem (1969) 3.86
Levels of translatable mRNAs for cell surface protein, collagen precursors, and two membrane proteins are altered in Rous sarcoma virus-transformed chick embryo fibroblasts. Proc Natl Acad Sci U S A (1977) 3.80
A simple method for determining the modulation transfer function in digital radiography. IEEE Trans Med Imaging (1992) 3.79
Lac DNA, RNA polymerase and cyclic AMP receptor protein, cyclic AMP, lac repressor and inducer are the essential elements for controlled lac transcription. Nat New Biol (1971) 3.79
The collagen gene: evidence for its evolutinary assembly by amplification of a DNA segment containing an exon of 54 bp. Cell (1980) 3.66
Promoter region of the human Harvey ras proto-oncogene: similarity to the EGF receptor proto-oncogene promoter. Science (1985) 3.59
Cyclic AMP levels in fibroblasts: relationship to growth rate and contact inhibition of growth. Biochem Biophys Res Commun (1971) 3.58
Cyclic AMP regulates catabolite and transient repression in E. coli. Nature (1969) 3.42
ADP-ribosylation. Annu Rev Biochem (1985) 3.30
Glucose depletion accounts for the induction of two transformation-sensitive membrane proteinsin Rous sarcoma virus-transformed chick embryo fibroblasts. Proc Natl Acad Sci U S A (1977) 3.26
Regulation of lac mRNA synthesis in a soluble cell-free system. Nat New Biol (1971) 3.25
Isolation and characterization of myosin from cloned mouse fibroblasts. Proc Natl Acad Sci U S A (1972) 3.24
Isolation and genetic characterization of human KB cell lines resistant to multiple drugs. Somat Cell Mol Genet (1985) 3.23
Human multidrug-resistant cell lines: increased mdr1 expression can precede gene amplification. Science (1986) 3.22
Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proc Natl Acad Sci U S A (1986) 3.19
A key role of starburst amacrine cells in originating retinal directional selectivity and optokinetic eye movement. Neuron (2001) 3.18
Reduced drug accumulation in multiply drug-resistant human KB carcinoma cell lines. Cancer Res (1985) 3.15
The human multidrug resistance (mdr1) gene. cDNA cloning and transcription initiation. J Biol Chem (1987) 3.13
Effect of adenosine 3',5'-monophosphate analogues on the activity of the cyclic adenosine 3',5'-monophosphate receptor in Escherichia coli. J Biol Chem (1972) 3.08
Poly(ADP-ribose) and ADP-ribosylation of proteins. Annu Rev Biochem (1977) 3.08
The major cell surface glycoprotein of chick embryo fibroblasts is an agglutinin. Proc Natl Acad Sci U S A (1975) 3.06
Amplification and enhanced expression of the epidermal growth factor receptor gene in A431 human carcinoma cells. Science (1984) 3.06
Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population: the Hisayama Study. Neurology (1995) 2.99
Microfilament bundles and cell shape are related to adhesiveness to substratum and are dissociable from growth control in cultured fibroblasts. Cell (1977) 2.99
Multiple drug-resistant human KB carcinoma cells independently selected for high-level resistance to colchicine, adriamycin, or vinblastine show changes in expression of specific proteins. J Biol Chem (1986) 2.93
Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli. Cell (1987) 2.93
The role of the lac promotor locus in the regulation of beta-galactosidase synthesis by cyclic 3',5'-adenosine monophosphate. Proc Natl Acad Sci U S A (1968) 2.92
The visualization of fluorescent proteins in living cells by video intensification microscopy (VIM). Cell (1978) 2.89
HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry (1998) 2.87
Regulation of cell growth by cyclic adenosine 3',5'-monophosphate. Effect of cell density and agents which alter cell growth on cyclic adenosine 3',5'-monophosphate levels in fibroblasts. J Biol Chem (1972) 2.85
Multiple-drug resistance in human cancer. N Engl J Med (1987) 2.76
Adenovirus-induced release of epidermal growth factor and pseudomonas toxin into the cytosol of KB cells during receptor-mediated endocytosis. Cell (1983) 2.74
Effect of Rho on transcription of bacterial operons. Nat New Biol (1973) 2.74
Bleed of and biologic response to triglyceride filler used in radiolucent breast implants. Plast Reconstr Surg (1996) 2.69
Is the multidrug transporter a flippase? Trends Biochem Sci (1992) 2.68
Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med (2001) 2.65
Characterization of bacteriophage lambda reverse as an Escherichia coli phage carrying a unique set of host-derived recombination functions. J Mol Biol (1974) 2.64
The multidrug transporter, a double-edged sword. J Biol Chem (1988) 2.61
Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein. Nature (1988) 2.55
Fluorescent cellular indicators are extruded by the multidrug resistance protein. J Biol Chem (1993) 2.52
Induction of two transformation-sensitive membrane polypeptides in normal fibroblasts by a block in glycoprotein synthesis or glucose deprivation. Cell (1977) 2.52
Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer (1992) 2.50
Unusual features in the nucleotide sequence of a cDNA clone derived from the common region of avian sarcoma virus messenger RNA. Proc Natl Acad Sci U S A (1980) 2.45
ATP-dependent transport of vinblastine in vesicles from human multidrug-resistant cells. Proc Natl Acad Sci U S A (1988) 2.44
alpha-Galactosidase A deficient mice: a model of Fabry disease. Proc Natl Acad Sci U S A (1997) 2.43
Morphologic characterization of the pathway of transferrin endocytosis and recycling in human KB cells. Proc Natl Acad Sci U S A (1984) 2.42
Amines inhibit the clustering of alpha2-macroglobulin and EGF on the fibroblast cell surface. Nature (1979) 2.41
Clostridium barkeri sp. n. J Bacteriol (1972) 2.38
Unusual methylation pattern of the alpha 2 (l) collagen gene. Cell (1982) 2.36
Human epidermal growth factor receptor cDNA is homologous to a variety of RNAs overproduced in A431 carcinoma cells. Nature (1984) 2.36
P-glycoprotein and multidrug resistance. Curr Opin Genet Dev (1996) 2.33